nodes	percent_of_prediction	percent_of_DWPC	metapath
Ticagrelor—ABCB1—Tamoxifen—pancreatic cancer	0.0815	0.133	CbGbCtD
Ticagrelor—ABCB1—Gemcitabine—pancreatic cancer	0.0702	0.115	CbGbCtD
Ticagrelor—ABCB1—Erlotinib—pancreatic cancer	0.0693	0.113	CbGbCtD
Ticagrelor—ABCB1—Irinotecan—pancreatic cancer	0.0626	0.102	CbGbCtD
Ticagrelor—CYP3A4—Tamoxifen—pancreatic cancer	0.0488	0.0797	CbGbCtD
Ticagrelor—ABCB1—Docetaxel—pancreatic cancer	0.0459	0.0749	CbGbCtD
Ticagrelor—ABCB1—Sunitinib—pancreatic cancer	0.0456	0.0745	CbGbCtD
Ticagrelor—CYP3A4—Erlotinib—pancreatic cancer	0.0415	0.0678	CbGbCtD
Ticagrelor—CYP3A4—Irinotecan—pancreatic cancer	0.0375	0.0612	CbGbCtD
Ticagrelor—ABCB1—Doxorubicin—pancreatic cancer	0.0342	0.0558	CbGbCtD
Ticagrelor—CYP3A4—Docetaxel—pancreatic cancer	0.0275	0.0449	CbGbCtD
Ticagrelor—CYP3A4—Sunitinib—pancreatic cancer	0.0274	0.0447	CbGbCtD
Ticagrelor—CYP3A4—Doxorubicin—pancreatic cancer	0.0205	0.0334	CbGbCtD
Ticagrelor—Renal failure acute—Epirubicin—pancreatic cancer	0.0005	0.00151	CcSEcCtD
Ticagrelor—Epistaxis—Docetaxel—pancreatic cancer	0.000497	0.0015	CcSEcCtD
Ticagrelor—Asthenia—Tamoxifen—pancreatic cancer	0.000495	0.0015	CcSEcCtD
Ticagrelor—Chest pain—Gemcitabine—pancreatic cancer	0.000494	0.00149	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000491	0.00148	CcSEcCtD
Ticagrelor—Confusional state—Irinotecan—pancreatic cancer	0.000491	0.00148	CcSEcCtD
Ticagrelor—Asthenia—Erlotinib—pancreatic cancer	0.00049	0.00148	CcSEcCtD
Ticagrelor—Pruritus—Tamoxifen—pancreatic cancer	0.000488	0.00147	CcSEcCtD
Ticagrelor—Chest pain—Fluorouracil—pancreatic cancer	0.000486	0.00147	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000483	0.00146	CcSEcCtD
Ticagrelor—Pruritus—Erlotinib—pancreatic cancer	0.000483	0.00146	CcSEcCtD
Ticagrelor—Shock—Irinotecan—pancreatic cancer	0.000479	0.00145	CcSEcCtD
Ticagrelor—Nervous system disorder—Irinotecan—pancreatic cancer	0.000477	0.00144	CcSEcCtD
Ticagrelor—Haemoglobin—Docetaxel—pancreatic cancer	0.000476	0.00144	CcSEcCtD
Ticagrelor—Haemorrhage—Docetaxel—pancreatic cancer	0.000473	0.00143	CcSEcCtD
Ticagrelor—Cardiac failure—Epirubicin—pancreatic cancer	0.000473	0.00143	CcSEcCtD
Ticagrelor—Diarrhoea—Tamoxifen—pancreatic cancer	0.000472	0.00143	CcSEcCtD
Ticagrelor—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.000471	0.00142	CcSEcCtD
Ticagrelor—Confusional state—Fluorouracil—pancreatic cancer	0.00047	0.00142	CcSEcCtD
Ticagrelor—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000468	0.00141	CcSEcCtD
Ticagrelor—Abdominal pain—Sunitinib—pancreatic cancer	0.000467	0.00141	CcSEcCtD
Ticagrelor—Body temperature increased—Sunitinib—pancreatic cancer	0.000467	0.00141	CcSEcCtD
Ticagrelor—Diarrhoea—Erlotinib—pancreatic cancer	0.000467	0.00141	CcSEcCtD
Ticagrelor—Oedema peripheral—Docetaxel—pancreatic cancer	0.000466	0.00141	CcSEcCtD
Ticagrelor—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000465	0.00141	CcSEcCtD
Ticagrelor—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000465	0.0014	CcSEcCtD
Ticagrelor—Urethral disorder—Docetaxel—pancreatic cancer	0.000464	0.0014	CcSEcCtD
Ticagrelor—Renal failure acute—Doxorubicin—pancreatic cancer	0.000463	0.0014	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Epirubicin—pancreatic cancer	0.000462	0.0014	CcSEcCtD
Ticagrelor—Skin disorder—Gemcitabine—pancreatic cancer	0.00046	0.00139	CcSEcCtD
Ticagrelor—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000457	0.00138	CcSEcCtD
Ticagrelor—Dizziness—Tamoxifen—pancreatic cancer	0.000456	0.00138	CcSEcCtD
Ticagrelor—Hypotension—Irinotecan—pancreatic cancer	0.000455	0.00137	CcSEcCtD
Ticagrelor—Dizziness—Erlotinib—pancreatic cancer	0.000451	0.00136	CcSEcCtD
Ticagrelor—Hypotension—Gemcitabine—pancreatic cancer	0.000443	0.00134	CcSEcCtD
Ticagrelor—Eye disorder—Docetaxel—pancreatic cancer	0.000442	0.00134	CcSEcCtD
Ticagrelor—Cardiac disorder—Docetaxel—pancreatic cancer	0.000439	0.00133	CcSEcCtD
Ticagrelor—Vomiting—Tamoxifen—pancreatic cancer	0.000439	0.00133	CcSEcCtD
Ticagrelor—Cardiac failure—Doxorubicin—pancreatic cancer	0.000438	0.00132	CcSEcCtD
Ticagrelor—Paraesthesia—Irinotecan—pancreatic cancer	0.000437	0.00132	CcSEcCtD
Ticagrelor—Hypotension—Fluorouracil—pancreatic cancer	0.000435	0.00132	CcSEcCtD
Ticagrelor—Hypersensitivity—Sunitinib—pancreatic cancer	0.000435	0.00132	CcSEcCtD
Ticagrelor—Rash—Tamoxifen—pancreatic cancer	0.000435	0.00131	CcSEcCtD
Ticagrelor—Dermatitis—Tamoxifen—pancreatic cancer	0.000434	0.00131	CcSEcCtD
Ticagrelor—Vomiting—Erlotinib—pancreatic cancer	0.000434	0.00131	CcSEcCtD
Ticagrelor—Dyspnoea—Irinotecan—pancreatic cancer	0.000434	0.00131	CcSEcCtD
Ticagrelor—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000432	0.00131	CcSEcCtD
Ticagrelor—Headache—Tamoxifen—pancreatic cancer	0.000432	0.00131	CcSEcCtD
Ticagrelor—Rash—Erlotinib—pancreatic cancer	0.00043	0.0013	CcSEcCtD
Ticagrelor—Dermatitis—Erlotinib—pancreatic cancer	0.00043	0.0013	CcSEcCtD
Ticagrelor—Angiopathy—Docetaxel—pancreatic cancer	0.00043	0.0013	CcSEcCtD
Ticagrelor—Dyspepsia—Irinotecan—pancreatic cancer	0.000428	0.00129	CcSEcCtD
Ticagrelor—Immune system disorder—Docetaxel—pancreatic cancer	0.000428	0.00129	CcSEcCtD
Ticagrelor—Headache—Erlotinib—pancreatic cancer	0.000427	0.00129	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Doxorubicin—pancreatic cancer	0.000427	0.00129	CcSEcCtD
Ticagrelor—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000427	0.00129	CcSEcCtD
Ticagrelor—Paraesthesia—Gemcitabine—pancreatic cancer	0.000426	0.00129	CcSEcCtD
Ticagrelor—Asthenia—Sunitinib—pancreatic cancer	0.000424	0.00128	CcSEcCtD
Ticagrelor—Dyspnoea—Gemcitabine—pancreatic cancer	0.000423	0.00128	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00042	0.00127	CcSEcCtD
Ticagrelor—Fatigue—Irinotecan—pancreatic cancer	0.00042	0.00127	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—CCK—pancreatic cancer	0.000419	0.00738	CbGpPWpGaD
Ticagrelor—Paraesthesia—Fluorouracil—pancreatic cancer	0.000418	0.00126	CcSEcCtD
Ticagrelor—Pruritus—Sunitinib—pancreatic cancer	0.000418	0.00126	CcSEcCtD
Ticagrelor—Breast disorder—Epirubicin—pancreatic cancer	0.000417	0.00126	CcSEcCtD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.000417	0.00734	CbGpPWpGaD
Ticagrelor—Constipation—Irinotecan—pancreatic cancer	0.000416	0.00126	CcSEcCtD
Ticagrelor—Dyspnoea—Fluorouracil—pancreatic cancer	0.000415	0.00126	CcSEcCtD
Ticagrelor—Mental disorder—Docetaxel—pancreatic cancer	0.000415	0.00125	CcSEcCtD
Ticagrelor—P2RY12—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	0.000413	0.00729	CbGpPWpGaD
Ticagrelor—Malnutrition—Docetaxel—pancreatic cancer	0.000412	0.00125	CcSEcCtD
Ticagrelor—Dyspepsia—Fluorouracil—pancreatic cancer	0.00041	0.00124	CcSEcCtD
Ticagrelor—Nausea—Tamoxifen—pancreatic cancer	0.00041	0.00124	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000409	0.00124	CcSEcCtD
Ticagrelor—Fatigue—Gemcitabine—pancreatic cancer	0.000409	0.00124	CcSEcCtD
Ticagrelor—Gastritis—Epirubicin—pancreatic cancer	0.000409	0.00123	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—CNR2—pancreatic cancer	0.000408	0.00719	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR ligand binding—GLP1R—pancreatic cancer	0.000408	0.00719	CbGpPWpGaD
Ticagrelor—Constipation—Gemcitabine—pancreatic cancer	0.000405	0.00122	CcSEcCtD
Ticagrelor—Nausea—Erlotinib—pancreatic cancer	0.000405	0.00122	CcSEcCtD
Ticagrelor—Diarrhoea—Sunitinib—pancreatic cancer	0.000404	0.00122	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000402	0.00122	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—CCKAR—pancreatic cancer	0.000401	0.00707	CbGpPWpGaD
Ticagrelor—Feeling abnormal—Irinotecan—pancreatic cancer	0.000401	0.00121	CcSEcCtD
Ticagrelor—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.0004	0.00121	CcSEcCtD
Ticagrelor—Back pain—Docetaxel—pancreatic cancer	0.000399	0.0012	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000398	0.0012	CcSEcCtD
Ticagrelor—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—pancreatic cancer	0.000391	0.00689	CbGpPWpGaD
Ticagrelor—Dizziness—Sunitinib—pancreatic cancer	0.000391	0.00118	CcSEcCtD
Ticagrelor—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000391	0.00118	CcSEcCtD
Ticagrelor—Breast disorder—Doxorubicin—pancreatic cancer	0.000386	0.00117	CcSEcCtD
Ticagrelor—Body temperature increased—Irinotecan—pancreatic cancer	0.000385	0.00116	CcSEcCtD
Ticagrelor—Abdominal pain—Irinotecan—pancreatic cancer	0.000385	0.00116	CcSEcCtD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.000384	0.00678	CbGpPWpGaD
Ticagrelor—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000384	0.00116	CcSEcCtD
Ticagrelor—Gastritis—Doxorubicin—pancreatic cancer	0.000378	0.00114	CcSEcCtD
Ticagrelor—Vomiting—Sunitinib—pancreatic cancer	0.000376	0.00114	CcSEcCtD
Ticagrelor—Body temperature increased—Gemcitabine—pancreatic cancer	0.000375	0.00113	CcSEcCtD
Ticagrelor—Rash—Sunitinib—pancreatic cancer	0.000372	0.00113	CcSEcCtD
Ticagrelor—Dermatitis—Sunitinib—pancreatic cancer	0.000372	0.00112	CcSEcCtD
Ticagrelor—Headache—Sunitinib—pancreatic cancer	0.00037	0.00112	CcSEcCtD
Ticagrelor—Syncope—Docetaxel—pancreatic cancer	0.00037	0.00112	CcSEcCtD
Ticagrelor—Body temperature increased—Fluorouracil—pancreatic cancer	0.000368	0.00111	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—SHH—pancreatic cancer	0.000366	0.00645	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PRLHR—pancreatic cancer	0.000364	0.00642	CbGpPWpGaD
Ticagrelor—Loss of consciousness—Docetaxel—pancreatic cancer	0.000362	0.00109	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—IAPP—pancreatic cancer	0.000361	0.00637	CbGpPWpGaD
Ticagrelor—Cough—Docetaxel—pancreatic cancer	0.00036	0.00109	CcSEcCtD
Ticagrelor—Hypersensitivity—Irinotecan—pancreatic cancer	0.000359	0.00108	CcSEcCtD
Ticagrelor—Hypertension—Docetaxel—pancreatic cancer	0.000356	0.00108	CcSEcCtD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.000354	0.00624	CbGpPWpGaD
Ticagrelor—Chest pain—Docetaxel—pancreatic cancer	0.000351	0.00106	CcSEcCtD
Ticagrelor—Nausea—Sunitinib—pancreatic cancer	0.000351	0.00106	CcSEcCtD
Ticagrelor—Asthenia—Irinotecan—pancreatic cancer	0.000349	0.00106	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000348	0.00105	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—PTHLH—pancreatic cancer	0.000347	0.00611	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR ligand binding—PTCH1—pancreatic cancer	0.000347	0.00611	CbGpPWpGaD
Ticagrelor—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000343	0.00104	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000341	0.00602	CbGpPWpGaD
Ticagrelor—Asthenia—Gemcitabine—pancreatic cancer	0.00034	0.00103	CcSEcCtD
Ticagrelor—Haematuria—Epirubicin—pancreatic cancer	0.000339	0.00103	CcSEcCtD
Ticagrelor—Confusional state—Docetaxel—pancreatic cancer	0.000339	0.00103	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TFF1—pancreatic cancer	0.000338	0.00596	CbGpPWpGaD
Ticagrelor—Epistaxis—Epirubicin—pancreatic cancer	0.000336	0.00101	CcSEcCtD
Ticagrelor—Pruritus—Gemcitabine—pancreatic cancer	0.000335	0.00101	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—GDI1—pancreatic cancer	0.000334	0.00589	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—GDI2—pancreatic cancer	0.000334	0.00589	CbGpPWpGaD
Ticagrelor—Diarrhoea—Irinotecan—pancreatic cancer	0.000333	0.00101	CcSEcCtD
Ticagrelor—Shock—Docetaxel—pancreatic cancer	0.000331	0.001	CcSEcCtD
Ticagrelor—Nervous system disorder—Docetaxel—pancreatic cancer	0.00033	0.000997	CcSEcCtD
Ticagrelor—Pruritus—Fluorouracil—pancreatic cancer	0.00033	0.000996	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000327	0.00577	CbGpPWpGaD
Ticagrelor—Skin disorder—Docetaxel—pancreatic cancer	0.000327	0.000987	CcSEcCtD
Ticagrelor—Bradycardia—Epirubicin—pancreatic cancer	0.000325	0.000983	CcSEcCtD
Ticagrelor—Diarrhoea—Gemcitabine—pancreatic cancer	0.000324	0.00098	CcSEcCtD
Ticagrelor—Dizziness—Irinotecan—pancreatic cancer	0.000322	0.000972	CcSEcCtD
Ticagrelor—Haemoglobin—Epirubicin—pancreatic cancer	0.000321	0.00097	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—PPY—pancreatic cancer	0.000321	0.00566	CbGpPWpGaD
Ticagrelor—Haemorrhage—Epirubicin—pancreatic cancer	0.000319	0.000965	CcSEcCtD
Ticagrelor—Diarrhoea—Fluorouracil—pancreatic cancer	0.000319	0.000964	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—SST—pancreatic cancer	0.000317	0.00559	CbGpPWpGaD
Ticagrelor—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000315	0.000953	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000315	0.00555	CbGpPWpGaD
Ticagrelor—Oedema peripheral—Epirubicin—pancreatic cancer	0.000315	0.000951	CcSEcCtD
Ticagrelor—Hypotension—Docetaxel—pancreatic cancer	0.000314	0.00095	CcSEcCtD
Ticagrelor—Haematuria—Doxorubicin—pancreatic cancer	0.000314	0.000948	CcSEcCtD
Ticagrelor—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000314	0.000948	CcSEcCtD
Ticagrelor—Urethral disorder—Epirubicin—pancreatic cancer	0.000313	0.000946	CcSEcCtD
Ticagrelor—Epistaxis—Doxorubicin—pancreatic cancer	0.00031	0.000938	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—SSTR3—pancreatic cancer	0.00031	0.00546	CbGpPWpGaD
Ticagrelor—Vomiting—Irinotecan—pancreatic cancer	0.000309	0.000935	CcSEcCtD
Ticagrelor—Dizziness—Fluorouracil—pancreatic cancer	0.000308	0.000931	CcSEcCtD
Ticagrelor—Rash—Irinotecan—pancreatic cancer	0.000307	0.000927	CcSEcCtD
Ticagrelor—Dermatitis—Irinotecan—pancreatic cancer	0.000307	0.000926	CcSEcCtD
Ticagrelor—Headache—Irinotecan—pancreatic cancer	0.000305	0.000921	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000304	0.00536	CbGpPWpGaD
Ticagrelor—Paraesthesia—Docetaxel—pancreatic cancer	0.000302	0.000913	CcSEcCtD
Ticagrelor—Vomiting—Gemcitabine—pancreatic cancer	0.000301	0.000911	CcSEcCtD
Ticagrelor—Bradycardia—Doxorubicin—pancreatic cancer	0.000301	0.000909	CcSEcCtD
Ticagrelor—Dyspnoea—Docetaxel—pancreatic cancer	0.0003	0.000906	CcSEcCtD
Ticagrelor—Rash—Gemcitabine—pancreatic cancer	0.000299	0.000903	CcSEcCtD
Ticagrelor—Dermatitis—Gemcitabine—pancreatic cancer	0.000299	0.000902	CcSEcCtD
Ticagrelor—Eye disorder—Epirubicin—pancreatic cancer	0.000298	0.000902	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—SSTR1—pancreatic cancer	0.000297	0.00524	CbGpPWpGaD
Ticagrelor—Haemoglobin—Doxorubicin—pancreatic cancer	0.000297	0.000898	CcSEcCtD
Ticagrelor—Headache—Gemcitabine—pancreatic cancer	0.000297	0.000897	CcSEcCtD
Ticagrelor—Cardiac disorder—Epirubicin—pancreatic cancer	0.000296	0.000896	CcSEcCtD
Ticagrelor—Vomiting—Fluorouracil—pancreatic cancer	0.000296	0.000896	CcSEcCtD
Ticagrelor—Dyspepsia—Docetaxel—pancreatic cancer	0.000296	0.000895	CcSEcCtD
Ticagrelor—Haemorrhage—Doxorubicin—pancreatic cancer	0.000295	0.000893	CcSEcCtD
Ticagrelor—Rash—Fluorouracil—pancreatic cancer	0.000294	0.000888	CcSEcCtD
Ticagrelor—Dermatitis—Fluorouracil—pancreatic cancer	0.000294	0.000887	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—CNR1—pancreatic cancer	0.000293	0.00516	CbGpPWpGaD
Ticagrelor—Headache—Fluorouracil—pancreatic cancer	0.000292	0.000882	CcSEcCtD
Ticagrelor—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000292	0.000882	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—PPY—pancreatic cancer	0.000291	0.00514	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CG—pancreatic cancer	0.000291	0.00513	CbGpPWpGaD
Ticagrelor—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000291	0.00088	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00029	0.000878	CcSEcCtD
Ticagrelor—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.00029	0.000878	CcSEcCtD
Ticagrelor—Fatigue—Docetaxel—pancreatic cancer	0.00029	0.000876	CcSEcCtD
Ticagrelor—Angiopathy—Epirubicin—pancreatic cancer	0.00029	0.000876	CcSEcCtD
Ticagrelor—Urethral disorder—Doxorubicin—pancreatic cancer	0.00029	0.000875	CcSEcCtD
Ticagrelor—Nausea—Irinotecan—pancreatic cancer	0.000289	0.000874	CcSEcCtD
Ticagrelor—Immune system disorder—Epirubicin—pancreatic cancer	0.000288	0.000872	CcSEcCtD
Ticagrelor—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000288	0.00087	CcSEcCtD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—EGF—pancreatic cancer	0.000288	0.00507	CbGpPWpGaD
Ticagrelor—Constipation—Docetaxel—pancreatic cancer	0.000288	0.000869	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—SSTR2—pancreatic cancer	0.000286	0.00504	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR ligand binding—GCG—pancreatic cancer	0.000283	0.00498	CbGpPWpGaD
Ticagrelor—Nausea—Gemcitabine—pancreatic cancer	0.000282	0.000851	CcSEcCtD
Ticagrelor—Mental disorder—Epirubicin—pancreatic cancer	0.00028	0.000846	CcSEcCtD
Ticagrelor—Malnutrition—Epirubicin—pancreatic cancer	0.000278	0.00084	CcSEcCtD
Ticagrelor—Feeling abnormal—Docetaxel—pancreatic cancer	0.000277	0.000838	CcSEcCtD
Ticagrelor—Nausea—Fluorouracil—pancreatic cancer	0.000277	0.000837	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—CCKBR—pancreatic cancer	0.000276	0.00487	CbGpPWpGaD
Ticagrelor—Eye disorder—Doxorubicin—pancreatic cancer	0.000276	0.000835	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000275	0.000831	CcSEcCtD
Ticagrelor—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000274	0.000829	CcSEcCtD
Ticagrelor—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000273	0.00482	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR ligand binding—AGTR1—pancreatic cancer	0.00027	0.00475	CbGpPWpGaD
Ticagrelor—Back pain—Epirubicin—pancreatic cancer	0.000269	0.000813	CcSEcCtD
Ticagrelor—Angiopathy—Doxorubicin—pancreatic cancer	0.000268	0.00081	CcSEcCtD
Ticagrelor—Immune system disorder—Doxorubicin—pancreatic cancer	0.000267	0.000807	CcSEcCtD
Ticagrelor—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000266	0.000805	CcSEcCtD
Ticagrelor—Abdominal pain—Docetaxel—pancreatic cancer	0.000266	0.000804	CcSEcCtD
Ticagrelor—Body temperature increased—Docetaxel—pancreatic cancer	0.000266	0.000804	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—CD44—pancreatic cancer	0.000264	0.00465	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—GAST—pancreatic cancer	0.000262	0.00461	CbGpPWpGaD
Ticagrelor—Mental disorder—Doxorubicin—pancreatic cancer	0.000259	0.000782	CcSEcCtD
Ticagrelor—Malnutrition—Doxorubicin—pancreatic cancer	0.000257	0.000777	CcSEcCtD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CD—pancreatic cancer	0.000256	0.00451	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—IFNA1—pancreatic cancer	0.000255	0.0045	CbGpPWpGaD
Ticagrelor—Vertigo—Epirubicin—pancreatic cancer	0.00025	0.000755	CcSEcCtD
Ticagrelor—Syncope—Epirubicin—pancreatic cancer	0.000249	0.000753	CcSEcCtD
Ticagrelor—Back pain—Doxorubicin—pancreatic cancer	0.000249	0.000752	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—SCT—pancreatic cancer	0.000248	0.00437	CbGpPWpGaD
Ticagrelor—Hypersensitivity—Docetaxel—pancreatic cancer	0.000248	0.000749	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—DAXX—pancreatic cancer	0.000245	0.00433	CbGpPWpGaD
Ticagrelor—Loss of consciousness—Epirubicin—pancreatic cancer	0.000244	0.000738	CcSEcCtD
Ticagrelor—Cough—Epirubicin—pancreatic cancer	0.000243	0.000733	CcSEcCtD
Ticagrelor—Asthenia—Docetaxel—pancreatic cancer	0.000241	0.000729	CcSEcCtD
Ticagrelor—Hypertension—Epirubicin—pancreatic cancer	0.00024	0.000725	CcSEcCtD
Ticagrelor—Pruritus—Docetaxel—pancreatic cancer	0.000238	0.000719	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—IFNA2—pancreatic cancer	0.000238	0.00419	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—GAST—pancreatic cancer	0.000238	0.00419	CbGpPWpGaD
Ticagrelor—Chest pain—Epirubicin—pancreatic cancer	0.000237	0.000715	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—CCK—pancreatic cancer	0.000237	0.00417	CbGpPWpGaD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000235	0.00071	CcSEcCtD
Ticagrelor—ABCB1—Allograft Rejection—AGTR1—pancreatic cancer	0.000232	0.00408	CbGpPWpGaD
Ticagrelor—Vertigo—Doxorubicin—pancreatic cancer	0.000231	0.000698	CcSEcCtD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—SMAD4—pancreatic cancer	0.000231	0.00407	CbGpPWpGaD
Ticagrelor—Syncope—Doxorubicin—pancreatic cancer	0.000231	0.000697	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—CNR2—pancreatic cancer	0.000231	0.00406	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000231	0.00406	CbGpPWpGaD
Ticagrelor—Diarrhoea—Docetaxel—pancreatic cancer	0.00023	0.000696	CcSEcCtD
Ticagrelor—Confusional state—Epirubicin—pancreatic cancer	0.000229	0.000691	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000227	0.004	CbGpPWpGaD
Ticagrelor—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000226	0.000683	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—SCT—pancreatic cancer	0.000225	0.00397	CbGpPWpGaD
Ticagrelor—Cough—Doxorubicin—pancreatic cancer	0.000224	0.000678	CcSEcCtD
Ticagrelor—Shock—Epirubicin—pancreatic cancer	0.000223	0.000675	CcSEcCtD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CB—pancreatic cancer	0.000223	0.00393	CbGpPWpGaD
Ticagrelor—Nervous system disorder—Epirubicin—pancreatic cancer	0.000222	0.000672	CcSEcCtD
Ticagrelor—Dizziness—Docetaxel—pancreatic cancer	0.000222	0.000672	CcSEcCtD
Ticagrelor—Hypertension—Doxorubicin—pancreatic cancer	0.000222	0.000671	CcSEcCtD
Ticagrelor—Skin disorder—Epirubicin—pancreatic cancer	0.00022	0.000666	CcSEcCtD
Ticagrelor—Chest pain—Doxorubicin—pancreatic cancer	0.000219	0.000662	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000217	0.000657	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—PRLHR—pancreatic cancer	0.000215	0.0038	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—CCK—pancreatic cancer	0.000215	0.00379	CbGpPWpGaD
Ticagrelor—Vomiting—Docetaxel—pancreatic cancer	0.000214	0.000646	CcSEcCtD
Ticagrelor—Rash—Docetaxel—pancreatic cancer	0.000212	0.000641	CcSEcCtD
Ticagrelor—Hypotension—Epirubicin—pancreatic cancer	0.000212	0.000641	CcSEcCtD
Ticagrelor—Dermatitis—Docetaxel—pancreatic cancer	0.000212	0.00064	CcSEcCtD
Ticagrelor—Confusional state—Doxorubicin—pancreatic cancer	0.000212	0.00064	CcSEcCtD
Ticagrelor—Headache—Docetaxel—pancreatic cancer	0.000211	0.000637	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—CNR2—pancreatic cancer	0.000209	0.00369	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—GLP1R—pancreatic cancer	0.000209	0.00369	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000208	0.00367	CbGpPWpGaD
Ticagrelor—Shock—Doxorubicin—pancreatic cancer	0.000207	0.000624	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—CCKAR—pancreatic cancer	0.000206	0.00363	CbGpPWpGaD
Ticagrelor—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000206	0.000622	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—IAPP—pancreatic cancer	0.000204	0.0036	CbGpPWpGaD
Ticagrelor—P2RY12—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.000204	0.0036	CbGpPWpGaD
Ticagrelor—Skin disorder—Doxorubicin—pancreatic cancer	0.000204	0.000616	CcSEcCtD
Ticagrelor—Paraesthesia—Epirubicin—pancreatic cancer	0.000204	0.000616	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—ACVR1B—pancreatic cancer	0.000202	0.00357	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—ZNRF3—pancreatic cancer	0.000202	0.00357	CbGpPWpGaD
Ticagrelor—Dyspnoea—Epirubicin—pancreatic cancer	0.000202	0.000611	CcSEcCtD
Ticagrelor—Nausea—Docetaxel—pancreatic cancer	0.0002	0.000604	CcSEcCtD
Ticagrelor—Dyspepsia—Epirubicin—pancreatic cancer	0.0002	0.000604	CcSEcCtD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—TERT—pancreatic cancer	0.000198	0.00348	CbGpPWpGaD
Ticagrelor—Hypotension—Doxorubicin—pancreatic cancer	0.000196	0.000593	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000196	0.00345	CbGpPWpGaD
Ticagrelor—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000196	0.000592	CcSEcCtD
Ticagrelor—Fatigue—Epirubicin—pancreatic cancer	0.000196	0.000591	CcSEcCtD
Ticagrelor—Constipation—Epirubicin—pancreatic cancer	0.000194	0.000586	CcSEcCtD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—HIF1A—pancreatic cancer	0.000189	0.00333	CbGpPWpGaD
Ticagrelor—Paraesthesia—Doxorubicin—pancreatic cancer	0.000189	0.00057	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—SHH—pancreatic cancer	0.000188	0.00331	CbGpPWpGaD
Ticagrelor—Dyspnoea—Doxorubicin—pancreatic cancer	0.000187	0.000566	CcSEcCtD
Ticagrelor—Feeling abnormal—Epirubicin—pancreatic cancer	0.000187	0.000565	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000186	0.000561	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—IAPP—pancreatic cancer	0.000185	0.00327	CbGpPWpGaD
Ticagrelor—Dyspepsia—Doxorubicin—pancreatic cancer	0.000185	0.000558	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—SSTR3—pancreatic cancer	0.000183	0.00323	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—DTX1—pancreatic cancer	0.000183	0.00323	CbGpPWpGaD
Ticagrelor—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000181	0.000548	CcSEcCtD
Ticagrelor—Fatigue—Doxorubicin—pancreatic cancer	0.000181	0.000547	CcSEcCtD
Ticagrelor—Constipation—Doxorubicin—pancreatic cancer	0.00018	0.000543	CcSEcCtD
Ticagrelor—Abdominal pain—Epirubicin—pancreatic cancer	0.000179	0.000542	CcSEcCtD
Ticagrelor—Body temperature increased—Epirubicin—pancreatic cancer	0.000179	0.000542	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—SST—pancreatic cancer	0.000179	0.00316	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—SRC—pancreatic cancer	0.000179	0.00315	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PTHLH—pancreatic cancer	0.000178	0.00314	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PTCH1—pancreatic cancer	0.000178	0.00314	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SSTR1—pancreatic cancer	0.000176	0.00309	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—VEGFA—pancreatic cancer	0.000174	0.00307	CbGpPWpGaD
Ticagrelor—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000173	0.000523	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—pancreatic cancer	0.000173	0.00305	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PPY—pancreatic cancer	0.000172	0.00303	CbGpPWpGaD
Ticagrelor—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000172	0.000519	CcSEcCtD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.00017	0.00299	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SSTR2—pancreatic cancer	0.000169	0.00298	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PLAU—pancreatic cancer	0.000169	0.00297	CbGpPWpGaD
Ticagrelor—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	0.000168	0.00297	CbGpPWpGaD
Ticagrelor—Hypersensitivity—Epirubicin—pancreatic cancer	0.000167	0.000505	CcSEcCtD
Ticagrelor—Body temperature increased—Doxorubicin—pancreatic cancer	0.000166	0.000502	CcSEcCtD
Ticagrelor—Abdominal pain—Doxorubicin—pancreatic cancer	0.000166	0.000502	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—CNR1—pancreatic cancer	0.000165	0.00292	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CCKBR—pancreatic cancer	0.000163	0.00288	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—SST—pancreatic cancer	0.000163	0.00287	CbGpPWpGaD
Ticagrelor—Asthenia—Epirubicin—pancreatic cancer	0.000163	0.000492	CcSEcCtD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000162	0.00286	CbGpPWpGaD
Ticagrelor—Pruritus—Epirubicin—pancreatic cancer	0.000161	0.000485	CcSEcCtD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	0.00016	0.00282	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—GCG—pancreatic cancer	0.00016	0.00282	CbGpPWpGaD
Ticagrelor—Diarrhoea—Epirubicin—pancreatic cancer	0.000155	0.000469	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—pancreatic cancer	0.000155	0.00273	CbGpPWpGaD
Ticagrelor—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000155	0.000467	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—DTX4—pancreatic cancer	0.000153	0.0027	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—GLI1—pancreatic cancer	0.000153	0.0027	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—IAPP—pancreatic cancer	0.000153	0.0027	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000152	0.00269	CbGpPWpGaD
Ticagrelor—Asthenia—Doxorubicin—pancreatic cancer	0.000151	0.000455	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—CNR1—pancreatic cancer	0.00015	0.00265	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CG—pancreatic cancer	0.00015	0.00265	CbGpPWpGaD
Ticagrelor—Dizziness—Epirubicin—pancreatic cancer	0.00015	0.000453	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000149	0.00263	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NRP1—pancreatic cancer	0.000149	0.00263	CbGpPWpGaD
Ticagrelor—Pruritus—Doxorubicin—pancreatic cancer	0.000149	0.000449	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—EGF—pancreatic cancer	0.000148	0.00261	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—GCG—pancreatic cancer	0.000145	0.00256	CbGpPWpGaD
Ticagrelor—Vomiting—Epirubicin—pancreatic cancer	0.000144	0.000436	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—HEY2—pancreatic cancer	0.000144	0.00253	CbGpPWpGaD
Ticagrelor—Diarrhoea—Doxorubicin—pancreatic cancer	0.000144	0.000434	CcSEcCtD
Ticagrelor—Rash—Epirubicin—pancreatic cancer	0.000143	0.000432	CcSEcCtD
Ticagrelor—Dermatitis—Epirubicin—pancreatic cancer	0.000143	0.000432	CcSEcCtD
Ticagrelor—Headache—Epirubicin—pancreatic cancer	0.000142	0.00043	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—GAST—pancreatic cancer	0.00014	0.00247	CbGpPWpGaD
Ticagrelor—Dizziness—Doxorubicin—pancreatic cancer	0.000139	0.00042	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—AGTR1—pancreatic cancer	0.000138	0.00244	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	0.000136	0.0024	CbGpPWpGaD
Ticagrelor—Nausea—Epirubicin—pancreatic cancer	0.000135	0.000407	CcSEcCtD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—pancreatic cancer	0.000134	0.00236	CbGpPWpGaD
Ticagrelor—Vomiting—Doxorubicin—pancreatic cancer	0.000133	0.000403	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—HEY1—pancreatic cancer	0.000133	0.00234	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SCT—pancreatic cancer	0.000133	0.00234	CbGpPWpGaD
Ticagrelor—Rash—Doxorubicin—pancreatic cancer	0.000132	0.0004	CcSEcCtD
Ticagrelor—Dermatitis—Doxorubicin—pancreatic cancer	0.000132	0.0004	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—PIK3CD—pancreatic cancer	0.000132	0.00233	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—pancreatic cancer	0.000132	0.00232	CbGpPWpGaD
Ticagrelor—Headache—Doxorubicin—pancreatic cancer	0.000132	0.000397	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—CCK—pancreatic cancer	0.000127	0.00224	CbGpPWpGaD
Ticagrelor—Nausea—Doxorubicin—pancreatic cancer	0.000125	0.000377	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—CNR2—pancreatic cancer	0.000124	0.00218	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—GLP1R—pancreatic cancer	0.000124	0.00218	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR ligand binding—CXCL8—pancreatic cancer	0.000124	0.00218	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CCKAR—pancreatic cancer	0.000122	0.00214	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—JAG2—pancreatic cancer	0.000118	0.00208	CbGpPWpGaD
Ticagrelor—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—pancreatic cancer	0.000116	0.00205	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MEN1—pancreatic cancer	0.000116	0.00205	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CB—pancreatic cancer	0.000115	0.00203	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—pancreatic cancer	0.000113	0.00199	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	0.000111	0.00196	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SHH—pancreatic cancer	0.000111	0.00196	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOTCH4—pancreatic cancer	0.00011	0.00194	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—IAPP—pancreatic cancer	0.00011	0.00193	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—CXCL8—pancreatic cancer	0.000106	0.00187	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PTHLH—pancreatic cancer	0.000105	0.00185	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PTCH1—pancreatic cancer	0.000105	0.00185	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	0.000102	0.0018	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—CASP3—pancreatic cancer	0.000102	0.00179	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	9.96e-05	0.00176	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	9.87e-05	0.00174	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—pancreatic cancer	9.7e-05	0.00171	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SST—pancreatic cancer	9.62e-05	0.0017	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.48e-05	0.00167	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—JAG1—pancreatic cancer	9.41e-05	0.00166	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOTCH3—pancreatic cancer	9.37e-05	0.00165	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—SRC—pancreatic cancer	9.22e-05	0.00162	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—VEGFA—pancreatic cancer	8.98e-05	0.00158	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CNR1—pancreatic cancer	8.87e-05	0.00156	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—NRAS—pancreatic cancer	8.87e-05	0.00156	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—VEGFA—pancreatic cancer	8.62e-05	0.00152	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CG—pancreatic cancer	8.61e-05	0.00152	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—GCG—pancreatic cancer	8.57e-05	0.00151	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.34e-05	0.00147	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—TGFB1—pancreatic cancer	8.24e-05	0.00145	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—AGTR1—pancreatic cancer	8.18e-05	0.00144	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—STK11—pancreatic cancer	8.06e-05	0.00142	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—TGFB1—pancreatic cancer	7.92e-05	0.0014	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—KRAS—pancreatic cancer	7.63e-05	0.00135	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CD—pancreatic cancer	7.57e-05	0.00133	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—TNF—pancreatic cancer	7.39e-05	0.0013	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	7.35e-05	0.0013	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.27e-05	0.00128	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SMAD4—pancreatic cancer	7.06e-05	0.00124	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	7.03e-05	0.00124	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CA—pancreatic cancer	7.01e-05	0.00124	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—CXCL8—pancreatic cancer	6.98e-05	0.00123	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—HES1—pancreatic cancer	6.89e-05	0.00121	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—TP53—pancreatic cancer	6.78e-05	0.0012	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CB—pancreatic cancer	6.6e-05	0.00116	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—HRAS—pancreatic cancer	6.49e-05	0.00114	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	6.41e-05	0.00113	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	6.35e-05	0.00112	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—CXCL8—pancreatic cancer	6.34e-05	0.00112	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TERT—pancreatic cancer	6.04e-05	0.00106	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—HIF1A—pancreatic cancer	5.78e-05	0.00102	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TSC2—pancreatic cancer	5.76e-05	0.00102	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—AKT1—pancreatic cancer	5.73e-05	0.00101	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—APOE—pancreatic cancer	5.64e-05	0.000994	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KDR—pancreatic cancer	5.52e-05	0.000974	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	5.4e-05	0.000952	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PRSS1—pancreatic cancer	5.26e-05	0.000928	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NFKBIA—pancreatic cancer	5.25e-05	0.000926	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOTCH1—pancreatic cancer	5.2e-05	0.000917	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CG—pancreatic cancer	5.09e-05	0.000897	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—NRAS—pancreatic cancer	5.09e-05	0.000897	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—EGF—pancreatic cancer	5.03e-05	0.000887	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	5.02e-05	0.000884	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	4.88e-05	0.000861	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	4.83e-05	0.000852	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	4.71e-05	0.000831	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—EGFR—pancreatic cancer	4.64e-05	0.000817	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ARG2—pancreatic cancer	4.56e-05	0.000805	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CD—pancreatic cancer	4.47e-05	0.000788	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.43e-05	0.000781	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—KRAS—pancreatic cancer	4.38e-05	0.000772	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	4.37e-05	0.00077	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	4.26e-05	0.00075	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CA—pancreatic cancer	4.02e-05	0.000709	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—TYMP—pancreatic cancer	3.99e-05	0.000703	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	3.92e-05	0.00069	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	3.91e-05	0.000689	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CB—pancreatic cancer	3.9e-05	0.000687	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	3.83e-05	0.000675	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CXCL8—pancreatic cancer	3.75e-05	0.00066	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—HRAS—pancreatic cancer	3.72e-05	0.000656	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	3.65e-05	0.000643	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—AKT1—pancreatic cancer	3.62e-05	0.000638	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	3.62e-05	0.000638	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CASP3—pancreatic cancer	3.59e-05	0.000632	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CCND1—pancreatic cancer	3.49e-05	0.000615	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CTNNB1—pancreatic cancer	3.46e-05	0.000609	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MMP9—pancreatic cancer	3.39e-05	0.000597	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PTEN—pancreatic cancer	3.37e-05	0.000594	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	3.32e-05	0.000586	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—AKT1—pancreatic cancer	3.29e-05	0.000579	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PRSS1—pancreatic cancer	3.24e-05	0.000572	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GLP1R—pancreatic cancer	3.22e-05	0.000567	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	3.22e-05	0.000567	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—DPYD—pancreatic cancer	3.16e-05	0.000558	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SRC—pancreatic cancer	3.12e-05	0.000551	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—VEGFA—pancreatic cancer	3.04e-05	0.000536	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—STAT3—pancreatic cancer	3.01e-05	0.000531	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NRAS—pancreatic cancer	3.01e-05	0.00053	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—SLC2A2—pancreatic cancer	3e-05	0.000529	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ARG2—pancreatic cancer	2.81e-05	0.000496	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MYC—pancreatic cancer	2.8e-05	0.000494	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TGFB1—pancreatic cancer	2.79e-05	0.000492	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—EGFR—pancreatic cancer	2.74e-05	0.000483	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.72e-05	0.000479	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KRAS—pancreatic cancer	2.59e-05	0.000456	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.46e-05	0.000433	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CA—pancreatic cancer	2.38e-05	0.000419	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CD44—pancreatic cancer	2.33e-05	0.00041	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TP53—pancreatic cancer	2.3e-05	0.000405	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GCG—pancreatic cancer	2.23e-05	0.000393	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—HRAS—pancreatic cancer	2.2e-05	0.000388	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—STK11—pancreatic cancer	2.1e-05	0.000369	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.98e-05	0.000349	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.95e-05	0.000344	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—AKT1—pancreatic cancer	1.94e-05	0.000342	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.85e-05	0.000326	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—TYMS—pancreatic cancer	1.8e-05	0.000318	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—APOE—pancreatic cancer	1.47e-05	0.000258	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CD44—pancreatic cancer	1.43e-05	0.000253	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GCG—pancreatic cancer	1.37e-05	0.000242	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.32e-05	0.000233	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—STK11—pancreatic cancer	1.29e-05	0.000228	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PPARG—pancreatic cancer	1.28e-05	0.000225	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.16e-05	0.000205	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.11e-05	0.000196	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.01e-05	0.000179	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PTGS2—pancreatic cancer	1e-05	0.000177	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—APOE—pancreatic cancer	9.03e-06	0.000159	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PTEN—pancreatic cancer	8.76e-06	0.000154	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	8.15e-06	0.000144	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PPARG—pancreatic cancer	7.87e-06	0.000139	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	7.17e-06	0.000126	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	6.25e-06	0.00011	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PTGS2—pancreatic cancer	6.19e-06	0.000109	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CA—pancreatic cancer	6.18e-06	0.000109	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PTEN—pancreatic cancer	5.4e-06	9.52e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—AKT1—pancreatic cancer	5.05e-06	8.9e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	3.81e-06	6.71e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.11e-06	5.48e-05	CbGpPWpGaD
